ArticleAnnals of medicine2026
Postoperative stimulated thyroglobulin and the ps-tg/TSH ratio enhance the 2025 ATA risk stratification for predicting radioiodine response in papillary thyroid carcinoma.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative stimulated thyroglobulin (ps-Tg) is an established biomarker for assessing treatment response in papillary thyroid carcinoma (PTC), but optimal integration of biochemical parameters into the 2025 American Thyroid Association (ATA) recurrence risk stratification system remains undefined. MATERIALS AND
methodsWe retrospectively analyzed 1,117 PTC patients who underwent first radioactive iodine (RAI) therapy at the First Affiliated Hospital of Jinan University between 2015 and 2021. Two models were built to estimate the probability of achieving an excellent response (ER) 1 year after RAI: Model 1 included all variables selected by LASSO (pathological N stage, 2025 ATA recurrence risk stratification, ps-Tg, ps-Tg/thyroid-stimulating hormone [TSH] ratio, and thyroglobulin antibody [TgAb]); Model 2 served as a control, including only pathological N stage and recurrence risk stratification. Model performance was evaluated using receiver operating characteristic (ROC) analysis, LASSO regression, decision curve analysis (DCA), and net reclassification improvement (NRI).
resultsROC analysis identified optimal cut-off values of 4.10 ng/mL for ps-Tg and 0.07 for the ps-Tg/TSH ratio (area under the curve [AUC] 0.856 and 0.843, respectively). In the training cohort, Model 1 outperformed Model 2 (AUC 0.862 vs. 0.614; R
conclusionBased on ps-Tg, the ps-Tg/TSH ratio, TgAb, pathological N stage, and the ATA 2025 recurrence risk stratification, the combined model showed good predictive value for 1-year ER after RAI therapy in patients with PTC. This model may serve as a complementary tool to existing postoperative risk assessment and provide additional support for follow-up stratification and individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.